Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron

Pediatric Blood and Cancer

Volumn 60, Issue 11, 2013, Pages 1747-1752

  Plummer, Ellen S ^a,b   Crary, Shelley E ^c   Mccavit, Timothy L ^a,b   Buchanan, George R ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Intravenous iron; Iron deficiency anemia; Low molecular weight iron dextran; Pediatric

Indexed keywords

HEMOGLOBIN; IRON; IRON DEXTRAN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CASE STUDY; CHEST TIGHTNESS; CHILD; CLINICAL ARTICLE; COUGHING; DIZZINESS; DRUG ERUPTION; DRUG TREATMENT FAILURE; DYSPNEA; HUMAN; INFANT; IRON DEFICIENCY ANEMIA; IRON THERAPY; LIP DISEASE; LIP SWELLING; NAUSEA; NUTRITION; OUTPATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; THROAT IRRITATION; WHEEZING;

INTRAVENOUS IRON; IRON DEFICIENCY ANEMIA; LOW MOLECULAR WEIGHT IRON DEXTRAN; PEDIATRIC;

ADOLESCENT; ANEMIA, IRON-DEFICIENCY; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATINICS; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; MALE; MOLECULAR WEIGHT;

EID: 84883751681     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24676     Document Type: Article

References (31)

1. Lozoff B, Georgieff MK. Iron deficiency and brain development. Semin Pediatr Neurol 2006; 13:158-165.
2. Cogswell ME, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. Am J Clin Nutr 2009; 89:1334-1342.
3. Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997; 277:973-976.
4. Grantham-McGregor S, Ani C. A review of studies on the effect of iron deficiency on cognitive development in children. J Nutr 2001; 131:649S-666S; discussion 666S-668S.
5. Madan N, Rusia U, Sikka M, et al. Developmental and neurophysiologic deficits in iron deficiency in children. Indian J Pediatr 2011; 78:58-64.
6. Auerbach M, Coyne D, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol 2008; 83:580-588.
7. Crary SE, Hall K, Buchanan GR. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer 2011; 56:615-619.
8. Mamula P, Piccoli DA, Peck SN, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34:286-290.
9. Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011; 86:860-862.
10. INFeD® [package insert]. Morristown, NJ: Watson Pharma, Inc.; 2009.
11. Auerbach M, Ballard H. Clinical use of intravenous iron: Administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010:338-347.
12. Auerbach M. Should intravenous iron be upfront therapy for iron deficiency anemia? Pediatr Blood Cancer 2011; 56:511-512.
13. Okam MM, Mandell E, Hevelone N, et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol 2012; 87:E123-E124.
14. Auerbach M, Ballard H, Glaspy J. Clinical update: Intravenous iron for anaemia. Lancet 2007; 369:1502-1504.
15. Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19:1571-1575.
16. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378-382.
17. Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29:423-426.
18. Critchley JDY. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): A systematic review. Transf Altern Transf Med 2007; 9:8-36.
19. Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000; 109:27-32.
20. Auerbach M. Ferumoxytol as a new, safer, easier-to-administer intravenous iron: Yes or no? Am J Kidney Dis 2008; 52:826-829.
21. Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008; 73:528-530.
22. Anbu AT, Kemp T, O'Donnell K, et al. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin. Acta Paediatr 2005; 94:1738-1741.
23. Leijn E, Monnens LA, Cornelissen EA. Intravenous iron supplementation in children on hemodialysis. J Nephrol 2004; 17:423-426.
24. Warady BA, Zobrist RH, Wu J, et al. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 2005; 20:1320-1327.
25. Warady BA, Zobrist RH, Finan E. Sodium ferric gluconate complex maintenance therapy in children on hemodialysis. Pediatr Nephrol 2006; 21:553-560.
26. Akarsu S, Taskin E, Yilmaz E, et al. Treatment of iron deficiency anemia with intravenous iron preparations. Acta Haematol 2006; 116:51-57.
27. Pinsk V, Levy J, Moser A, et al. Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia. Isr Med Assoc J 2008; 10:335-338.
28. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-A randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100:2503-2509.
29. Hedenus M, Birgegard G. The role of iron supplementation during epoietin treatment for cancer-related anemia. Med Oncol 2009; 26:105-115.
30. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001; 38:988-991.
31. Lu M, Cohen MH, Rieves D, et al. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85:315-319.